MA52756A - Compositions pharmaceutiques stables pour inhalateurs doseurs sous pression - Google Patents

Compositions pharmaceutiques stables pour inhalateurs doseurs sous pression

Info

Publication number
MA52756A
MA52756A MA052756A MA52756A MA52756A MA 52756 A MA52756 A MA 52756A MA 052756 A MA052756 A MA 052756A MA 52756 A MA52756 A MA 52756A MA 52756 A MA52756 A MA 52756A
Authority
MA
Morocco
Prior art keywords
inhalators
pharmaceutical compositions
stable pharmaceutical
pressurized dosing
dosing
Prior art date
Application number
MA052756A
Other languages
English (en)
Inventor
Agnes Colombani
Mukul Dalvi
Abhishek Gupta
Original Assignee
Lupin Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Inc filed Critical Lupin Inc
Publication of MA52756A publication Critical patent/MA52756A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4748Quinolines; Isoquinolines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0001Details of inhalators; Constructional features thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA052756A 2018-06-04 2019-06-04 Compositions pharmaceutiques stables pour inhalateurs doseurs sous pression MA52756A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862680173P 2018-06-04 2018-06-04

Publications (1)

Publication Number Publication Date
MA52756A true MA52756A (fr) 2021-04-14

Family

ID=66998507

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052756A MA52756A (fr) 2018-06-04 2019-06-04 Compositions pharmaceutiques stables pour inhalateurs doseurs sous pression

Country Status (8)

Country Link
US (1) US20210315842A1 (fr)
EP (1) EP3801457A1 (fr)
AU (1) AU2019282562A1 (fr)
EA (1) EA202092976A1 (fr)
JO (1) JOP20200314A1 (fr)
MA (1) MA52756A (fr)
WO (1) WO2019236559A1 (fr)
ZA (1) ZA202007890B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220040086A1 (en) * 2018-10-01 2022-02-10 Kindeva Drug Delivery L.P. Formulation and aerosol canisters, inhalers, and the like containing the formulation
JP2023513969A (ja) 2020-02-20 2023-04-04 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 緩衝化医薬製剤を含む加圧定量吸入器
GB2614901A (en) 2022-01-21 2023-07-26 Nanopharm Ltd Inhalable formulations
WO2023227782A1 (fr) 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. Formulation pharmaceutique pour aérosol-doseur pressurisé
WO2023227781A1 (fr) 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. Formulation pharmaceutique pour aérosol-doseur sous pression
US20240252475A1 (en) * 2023-01-26 2024-08-01 Somerset Therapeutics, Llc Tiotropium combination product compositions and related methods
WO2026006658A1 (fr) 2024-06-27 2026-01-02 Lupin Inc. Compositions pharmaceutiques stables pour inhalateurs doseurs sous pression

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060257324A1 (en) 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
EE05167B1 (et) 2000-05-22 2009-06-15 Chiesi Farmaceutici S.P.A. Stabiilsed farmatseutilised lahuspreparaadid survestatud doseerivatele inhalaatoritele
EP2319585A1 (fr) * 2002-08-29 2011-05-11 Cipla Ltd. Produits pharmaceutiques et compositions à base de salmétérol, de fluticasone et d'ipratropium ou de tiotropium
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20060140873A1 (en) 2004-12-27 2006-06-29 Chang Heng W Aerosol pharmaceutical compositions
WO2007020204A2 (fr) * 2005-08-12 2007-02-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Formulations d'hydrofluorocarbone en solution contenant du chlorhydrate de salbutamol ou du citrate de salbutamol
EP1982709A1 (fr) * 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Utilisation d'une composition comportant du formotérol et du dipropionate de béclométhasone pour la prévention ou le traitement d'une condition aiguë de l'asthme
CA2785321C (fr) * 2009-12-23 2018-08-21 Chiesi Farmaceutici S.P.A. Polytherapie pour bronchopneumopathie chronique obstructive (copd)
JP2013531056A (ja) * 2010-07-16 2013-08-01 シプラ・リミテッド R(+)ブデソニド及び1以上の気管支拡張剤を含む医薬組成物
US10179139B2 (en) * 2010-10-12 2019-01-15 Cipla Limited Pharmaceutical composition
US20120204871A1 (en) * 2011-02-10 2012-08-16 Julio Cesar Vega Stable, non-corrosive formulations for pressurized metered dose inhalers
EP2749280A3 (fr) * 2011-02-17 2014-08-20 Cipla Limited Composition pharmaceutique de glycopyrronium et formotérol
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition

Also Published As

Publication number Publication date
JOP20200314A1 (ar) 2020-12-06
EA202092976A1 (ru) 2021-03-16
ZA202007890B (en) 2022-06-29
AU2019282562A1 (en) 2021-01-21
EP3801457A1 (fr) 2021-04-14
US20210315842A1 (en) 2021-10-14
WO2019236559A1 (fr) 2019-12-12

Similar Documents

Publication Publication Date Title
MA52756A (fr) Compositions pharmaceutiques stables pour inhalateurs doseurs sous pression
IL310360B1 (en) Preparations containing complexes of cyclodextrin in solid state and an active ingredient for ophthalmic administration
EP3817722A4 (fr) Compositions pharmaceutiques comprenant du méloxicam
EP3256149A4 (fr) Formulations pour administration orale d'agents actifs
EP3280421A4 (fr) Compositions pharmaceutiques pour thérapie combinée
EP3368084A4 (fr) Compositions pharmaceutiques pour administration par voie transmuqueuse
IL275220A (en) Oral administration of active drug substances
EP3573614C0 (fr) Compositions pharmaceutiques pour thérapie combinée
EP3310343A4 (fr) Compositions implantables pour administration de médicaments et méthodes d'utilisation desdites compositions
EP3509573A4 (fr) Compositions pharmaceutiques pour l'administration d'un peptide
EP3442503A4 (fr) Composition injectable pour l'administration d'un agent biologiquement actif
MA49947A (fr) Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes
MA55015A (fr) Formulations pharmaceutiques
EP2981258A4 (fr) Formulations pharmaceutiques pour l'administration sous-cutanée de furosémide
SG11202010124SA (en) Stable pharmaceutical formulation
EP3313380A4 (fr) Composition pour l'administration d'agents actifs à un animal
EP3318259A4 (fr) Composition pharmaceutique stable pour administration par voie orale
PL3315117T3 (pl) Kompozycja do higieny jamy ustnej dostarczająca środki aktywne do pielęgnacji jamy ustnej
EP3302477A4 (fr) Formulations pharmaceutiques pour la libération prolongée d'ester de dinalbuphine de sébacoyle
EP3302443A4 (fr) Microcapsules mécano-sensibles pour l'administration de médicaments
EP3668991A4 (fr) Nanosupports pour l'administration de principes actifs
PL4027973T3 (pl) Formulacje do dostarczania leków
MA54095A (fr) Formulations pharmaceutiques aqueuses
MA53812A (fr) Compositions pharmaceutiques comprenant des anticorps anti-cd37 bispécifiques
EP3650024A4 (fr) Composition pharmaceutique pour administration par voie nasale